Thursday, October 4, 2012
VentiRx Pharmaceuticals, a clinical stage biopharmaceutical company focused on novel Toll-like receptor 8 (TLR8) agonists and antagonists, has formed an exclusive, world-wide collaboration with Celgene, an integrated global biopharmaceutical company, for the development of VTX-2337, a highly potent and selective TLR8 agonist for the treatment of cancer.
Acceleron Pharma has raised a $30M private financing. Celgene, one of Acceleron’s strategic partners, and all other existing investors participated in this financing. The proceeds will be used to expand and advance Acceleron’s clinical stage pipeline and to continue to support its highly productive research engine.
Agios Pharmaceuticals has secured $78 million in an oversubscribed Series C financing. The proceeds of this financing will be used to advance the company’s rapidly emerging portfolio of cancer metabolism therapeutics into the clinic and to expand research and development into inborn errors of metabolism (IEMs), a group of genetic disorders with high unmet medical need.
Foundation Medicine has reported a collaboration with Johnson & Johnson Pharmaceutical Research and Development. The collaboration is focused on using Foundation Medicine’s comprehensive clinical cancer genomic test to identify potential biomarkers to support J&JPRD oncology clinical development programs. Financial details of the agreement were not disclosed.
Acceleron Pharma and Celgene have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia. The companies already have a collaboration around sotatercept (ACE-011) entered in 2008. Under the new agreement, the companies will collaborate to develop both products and potentially others for treating anemia across a wide range of indications.